Trial Profile
Phase I Study of Escalating Doses of IM-862 [oglufanide] in Patients With Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Oglufanide (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Pharmacodynamics
- 22 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Sep 2005 New trial record.